Li-Fraumeni syndrome (LFS) is a rare autosomal dominant inherited genetic disorder that greatly increases the risk of developing several types of cancer, including young children and young adults. LFS is primarily caused by specific mutations in the tumor suppressor gene TP53. In this study, we successfully generated two human induced pluripotent stem cell (iPSC) lines derived from patients diagnosed with LFS, each carrying a distinct heterozygous mutation in the TP53 gene. These LFS patient-derived iPSC lines exhibited robust expression of key pluripotency markers, demonstrated the capacity to differentiate into all three germ layers (endoderm, mesoderm, and ectoderm), and maintained a normal karyotype. The establishment of these iPSC lines provides a valuable tool for modeling LFS in vitro, enabling researchers to investigate the underlying pathological mechanisms associated with the disease across various cell types and tissues.
Keyphrases
- induced pluripotent stem cells
- stem cells
- young adults
- high glucose
- genome wide
- endothelial cells
- copy number
- end stage renal disease
- diabetic rats
- ejection fraction
- chronic kidney disease
- poor prognosis
- newly diagnosed
- case report
- single cell
- gene expression
- drug induced
- papillary thyroid
- cell therapy
- prognostic factors
- peritoneal dialysis
- dna methylation
- genome wide identification
- childhood cancer
- transcription factor
- patient reported outcomes
- lymph node metastasis